Signal Desk · Companies

Alembic Pharma gets USFDA nod for Binimetinib tablets

2026-11-15 · 1 source · Business Standard Companies

In short

Alembic Pharmaceuticals got final approval from the US FDA for Binimetinib tablets, a medicine used for lung cancer. The company said the generic matches Array BioPharma’s Mektovi Tablets and comes in 15 mg and 45 mg strengths.

The approval gives Alembic a chance at 180 days of generic exclusivity. That can help the company in the US generic drug market.

What the reporting says

Alembic Pharmaceuticals received final USFDA approval for its Abbreviated New Drug Application for Binimetinib tablets used to treat lung cancer. The company said the approved generic is therapeutically equivalent to Array BioPharma’s reference drug Mektovi Tablets. Alembic is eligible for 180 days of generic drug exclusivity for Binimetinib Tablets in 15 mg and 45 mg strengths, after being among the first applicants for the 15 mg version.

Why it matters

Alembic Pharmaceuticals has secured USFDA approval for Binimetinib tablets, a generic version of Array BioPharma’s Mektovi Tablets. The approval covers 15 mg and 45 mg strengths and could give Alembic 180 days of generic exclusivity. The development matters for Alembic’s US generics business and for the treatment market linked to lung cancer medicines.

Touches: Alembic Pharmaceuticals, Array BioPharma, Healthcare, Companies

Sources